File:Enalapril_structure.svg · Wikimedia Commons · See Wikimedia Commons
enalapril
Sign in to saveAlso known as Enaladex®, Vasotec®, 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester, (S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline, (S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline, Analapril, Enalaprilum
Enalapril, sold under the brand name Vasotec among others, is an ACE inhibitor medication used to treat high blood pressure, diabetic kidney disease, and heart failure. For heart failure, it is generally used with a diuretic, such as furosemide. It is given by mouth or by injection into a vein. Onset of effects are typically within an hour when taken by mouth and last for up to a day.
OverviewAI-generated
Enalapril is a chemical compound with the molecular formula C₂₀H₂₈N₂O₅. Its IUPAC name is (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid. The substance has a mass of 376.199822 and a weight of 376.4. It is characterized by a charge of 0, an xlogp value of -0.1, and a topological polar surface area of 95.9. The molecule contains two hydrogen bond donors and six hydrogen bond acceptors.
The defined daily dose for enalapril is 10. It is associated with the MCN code 2933.99.46. In scientific literature, the term enalapril appears in 9382 PubMed records. The compound is referenced by 124 other encyclopedia articles.
Synthesized by Vinony from 21 facts across 4 sources: Wikidata, PubMed, PubChem, Vinony graph. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 458951007
- Drug.image
- Enalapril structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 222
- Drug.image2
- Enalapril ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Vasotec, Renitec, Enacard, others
- Drug.MedlinePlus
- a686022
- Drug.DailyMedID
- Enalapril
- Drug.pregnancy_AU
- D
- Drug.pregnancy_category
- Contraindicated
- Drug.routes_of_administration
- By mouth
- Drug.class
- ACE inhibitor
- Drug.ATC_prefix
- C09
- Drug.ATC_suffix
- AA02
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C20H28N2O5
- Molecular weight
- 376.4 g/mol
- IUPAC name
- (2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
- SMILES
- CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
- InChIKey
- GBXSMTUPTTWBMN-XIRDDKMYSA-N
- XLogP
- -0.1
- Polar surface area
- 95.9 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
9,382 papers- Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).The New England journal of medicine · 1987
- Pharmacogenetic study of CES1 gene and enalapril efficacy.Journal of applied genetics · 2024
- Enalapril: a review of human pharmacology.Drugs · 1985
- Fixed-dose combination lercanidipine/enalapril.Drugs · 2007
- Enalapril: a long-acting angiotensin-converting enzyme inhibitor.Pharmacotherapy · 1987
via PubMed
~8 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- Mechanism of action
- Pharmacokinetics
- Structure activity relationship
- History
- Society and culture
- Legal status
- References
{{Infobox drug | Watchedfields = changed | verifiedrevid = 458951007 | image = Enalapril structure.svg | image_class = skin-invert-image | width = 222 | alt = | image2 = Enalapril ball-and-stick model.png | image_class2 = bg-transparent | width2 = | alt2 = | caption =
| pronounce = | tradename = Vasotec, Renitec, Enacard, others | Drugs.com = | MedlinePlus = a686022 | DailyMedID = Enalapril | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category = Contraindicated | routes_of_administration = By mouth | class = ACE inhibitor | ATC_prefix = C09 | ATC_suffix = AA02 | ATC_supplemental =
Excerpted from Wikipedia’s “enalapril” article, available under the CC BY-SA 4.0 licence.